Pfizer Study - A Phase 11 Trial of the Intravenous PARP Inhibitor AG-014699 in Combination with Five Days Oral Temozolomide given Every Four Weeks in Metastatic Melonoma.

Project Details

Short titlePfizer Study - A Phase 11 Trial of the Intravenous PARP Inhibitor AG-014699 in Combination with Five Days Oral Temozolomide given Every Four Weeks in Metastatic Melonoma.
StatusFinished
Effective start/end date1/06/05 → 31/12/08

Funding

  • Queen Elizabeth Hospital Birmingham